Please visit the European Cancer Congress Searchable Program for a full list of poster and presentation abstracts.


X


Saturday, September 26th, 2015

Poster Session: Diagnostic/Biomarkers

Comprehensive Genomic Profiling of Advanced Cancers Identifies MET Exon 14 Alterations That Are Sensitive to MET Inhibitors

Time / Location: 4:45 PM CEST/ Hall C

Abstract / Poster Number: 464 / #114

Presenter: Garrett Frampton, Ph.D., Senior Bioinformatics Scientist, Foundation Medicine

 

Poster Session: Diagnostic/Biomarkers

Candidate Biomarkers of PARP Inhibitor Sensitivity in Ovarian Cancer Beyond the BRCA Genes

Time / Location: 4:45 PM CEST/ Hall C

Abstract / Poster Number: 435 / #85

Presenter / Collaborator: Darren Hodgson, Ph.D., AstraZeneca / AstraZeneca

 

Sunday, September 27th, 2015

Poster Discussion Session: Head and Neck Cancer

High Prevalent BRAF Alterations and TERT Promoter Mutations in Papillary Thyroid Carcinoma

Time / Location: 9:15 AM CEST/ Hall C

Abstract / Poster Number: 2879 / #262

Presenter / Collaborators: Kai Wang, M.D., Ph.D., Senior Scientist, Technical Supervisor, Clinical Next Generation Sequencing, Foundation Medicine / CINJ Willamette Valley Cancer Institute, NYU, UC Irvine

 

Poster Discussion Session: Head and Neck Cancer

Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma

Time / Location: 9:15 AM CEST/ Hall C

Abstract / Poster Number: 2813 / #196

Presenter / Collaborators: Siraj Ali, M.D., Ph.D., Director, Clinical Development and Medical Affairs, Foundation Medicine / MD Anderson Cancer Center Ohio State University

 

Monday, September 28th, 2015

Proffered Paper Session: Lung Cancer - Metastatic Disease

Comprehensive Genomic Profiling Characterizes the Spectrum of non-V600E Activating BRAF Alterations Including BRAF Fusions in Lung Cancer

Time / Location: 9:15 AM CEST/ Strauss

Abstract / Presenter: 3007 / Siraj Ali, M.D., Ph.D., Director, Clinical Development and Medical Affairs, Foundation Medicine

 

Poster Session: Genitourinary Malignancies - Nonprostate Cancer

Comprehensive Genomic Profiling of Advanced Penile Carcinoma Suggests A High Rate of Clinically Relevant Genomic Alterations

Time / Location: 4:45 PM CEST / Hall C

Abstract / Poster Number: 2641 / #132

Presenter: Siraj Ali, M.D., Ph.D., Director, Clinical Development and Medical Affairs, Foundation Medicine

 

Poster Session: Genitourinary Malignancies - Nonprostate Cancer

Comprehensive Genomic Profiling (CGP) Identifies Unique and Abundant Clinically Relevant Genomic Alterations in Rare Histologies of Renal Cell Carcinoma

Time / Location: 4:45 PM CEST / Hall C

Abstract / Poster Number: 2651 / #142

Presenter: Siraj Ali, M.D., Ph.D., Director, Clinical Development and Medical Affairs, Foundation Medicine

 

Poster Session: New Technologies in Cancer

Therapeutically Relevant Extracellular Domain Mutations in ERBB2/HER2 are Observed Across Multiple Tumor Types and Are Associated with Major Responses to anti-HER2 Targeted Therapies

Time / Location: 4:45 PM CEST / Hall C

Abstract / Poster Number: 801 / #144

Presenter:Jeffrey S. Ross, M.D., Medical Director, Foundation Medicine

Tuesday, September 29th, 2015

Proffered Paper Session: Gynaecological Cancer

Final results of ARIEL2 (Part 1): A phase 2 trial to prospectively identify ovarian cancer (OC) responders to rucaparib using tumor genetic analysis

Time / Location: 9:00 AM CEST/ Hall A2

Abstract / Presenter: 2700 / Rebecca Kristeleit, Ph.D., University College Hospital

Collaborator: Clovis Oncology


Proffered Paper Session: Gynaecological Cancer

Quantification of Genomic Loss of Heterozygosity Enables Prospective Selection of Ovarian Cancer Patients Who May Derive Benefit From the PARP Inhibitor Rucaparib

Time / Location: 9:15 AM CEST / Hall A2

Abstract / Presenter: 2701 / Amit M. Oza, M.D., Princess Margaret Cancer Centre

Collaborator: Clovis Oncology